HU, JIALIANG

Release date:2016-05-13  Release:



HU,JIALIANG

Professor of Microbiology and Biochemical Pharmacy

School of Life Science and Biotechnology

Phone: 15005161104

Email: jialiang_hu51@aliyun.com

Research Summary

Professor HU’s research focuses on peptide drugs with anti-tumor and anti-inflammation activity. After design, syhthesis and screening of a peptide library, his group obtained peptidei nhibitors for matrix metalloproteinases. Lator on, by connection of a peptide inhibitor to an aniogenesis inhibiting peptide fragment, he designed peptide P2, which has been confirmed to have a high anti-inflammatory and anti-tumor activity. He is now interested in the basic mechanistic study of peptide drugs.

Education

2006 Ph.D., Immunobiology, the Univeristy of Leuven

2000 M.S., Biochemical Pharmacy, China Pharmaceutical University

1997 B.S., Biological Pharmaceitics, China Pharmaceutical University

Academic Experience

2018-      Professor of Microbiology and Biochemical Pharmacy, China Pharmaceutical University

2006-2007Postdoctor of immunobiology, the University of Leuven

Awards and Honors

2014       First Prize, for Pharmacy Development in Jiangsu Province, Association of Drug Research and Dvelopment in Jiangsu Province

Publications

  1. Zheng Qiu, Fengguo Zhang, Chengxin Gong, Hanmei Xu*, Jialiang Hu*. Fusion peptides CPU1 and CPU2 inhibit matrix metalloproteinases and protect mice from endotoxin shock within a strict time window. Inflammation. 2015, 38(6):2092-104.

  2. Jialiang Hu#, Tao Cheng#, Lijun Zhang, Beicheng Sun, Lei Deng, Hanmei Xu*. An anti-tumor peptide AP25 decreased cyclin D1 expression and inhibited MGC-803 proliferation via signal transduction pathways with p-ERK, Src, JNK and PI3K as key enzymes. Molecular Medicine Reports. 2015, 12(3):4396-402. doi: 10.3892/mmr.2015.3912.

  3. Zheng Qiu, Jianghai Chen, Hanmei Xu, Philippe E. Van den Steen, Ghislain Opdenakker, Min Wang* and Jialiang Hu*. Inhibition of neutrophil collagenase/MMP-8 and gelatinase B/MMP-9 and protection against endotoxin shock. Journal of Immunology Research. 2014.2014: 747426.

  4. Shen Hong*, Han Haibing*, Hu Jialiang, Zhang Xiaojuan, Wang jingjing, Wang Wenjing, Nie Caihui, Xu Hanmei. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. J. Mater. Chem. B, 2014, 2, 800.

  5. Jialiang Hu, Ming Yan, ChunyanPu, Jingjing Wang, Philippe E. Van den steen, GhislainOpdenakker, HanmeiXu*. Chemically synthesized matrix metalloproteinase- and angiogenesis-inhibiting peptides as anticancer agents. Anti-cancer Reagents ME. 2014 Mar;14(3):483-94.

  6. ZhengQiu#, Jialiang Hu#, HanmeiXu, Wenjing Wang, ChunyanPu, Xiang Wang. Generation of anti-tumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment. Anti-Cancer Drugs.2013, 24:677-689.

  7. 王文静,胡加亮,徐寒梅。整合素阻断剂类药物的研究与开发进展。中国当代医学. 2013,2017):29-35.

  8. 李永兵, 张奉国,胡加亮, 徐寒梅. 整合素阻断剂AP25单克隆抗体的制备与鉴定[J]. 江苏医药. 2013396):636-638.

  9. ZhengQiu, Ming Yan, Qian Li, Datao Liu, Philippe E. Van den Steen, Min Wang, GhislainOpdenakker, JialiangHu*.Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).J Enzyme Inhib Med Chem. 2012, 27(4):533-40.

  10. 邱郑,胡加亮*,吴海春,吴宏坚。基质金属蛋白酶和肿瘤坏死因子释放酶选择性多肽抑制剂HQ1-HQ4对内毒素休克的保护作用的研究。药物生物技术,2012, 19471-475.

  11. ChunyanPu, HanmeiXu*, Jialiang Hu, HengZheng, Xiaofeng Huang, Chi Zhang, Yongjing Yang and Yongbing Li. RGD-modified endostatin fragments showed anti-tumor effect via anti-angiogenesis.Anti-Cancer Drugs, 2012, 23(8):788-802.

  12. Li Pan, Jialiang Hu, Wenjing Wang, Xiaojuan Zhang, Jin Wei, Zhendong Liu, Yihua Zhang*, HanmeiXu *. Improvement of choroidal blood flow and inhibition of choroidal neovascularization by (R, R) ZX-5. Int. J. Mol. Sci., 2012, 13, 2717-2726.

  13. ZhengQiu, JialiangHu, Philippe E. Van den Steen, GhislainOpdenakker.Targeting matrix metalloproteinases in acute inflammatory shock syndromes.Comb Chem High Throughput Screen. 2012, 15(7):555-70.

  14. YongbingLi, HanmeiXu*, JialiangHu, FengguoZhang, ZhengdongLiu, Chi Zhang, YongjingYang, ChunyanPu, LinqiuHuang, XinWen. QuantitativeAnalysis and PharmacokineticsStudy of IntegrinAntagonistAP25 in RatPlasma. Protein Pept Lett. 2013 May;20(5):584-90

  15. 程涛, 胡加亮, 徐寒梅*. 整合素阻断剂抗肿瘤药物研究进展[J]. 中国医药科学. 2012, 221):44-47.

  16. 杨永晶, 徐寒梅*, 胡加亮. 以整合素为靶点的抗肿瘤药物研究进展[J]. 药物生物技术. 2012, 19(3): 256-260.

  17. 浦春艳, 徐寒梅*, 胡加亮. RGD修饰多肽EDSM-Y的克隆、表达、纯化和初步活性研究[J]. 药物生物技术. 2012, 19(3): 189-194.

  18. 邱郑, 胡加亮*, 王旻. 肿瘤多肽疫苗的临床应用。药物生物技术,201017538-544.

  19. Qiu Z, Dillen C, Hu J, Verbeke H, Struyf S, Van Damme J, Opdenakker G. 2009. Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes.Immunobiology. 214:835-42.

  20. Piccard H, Hu J, Fiten P, Proost P, Martens E, Van den Steen PE, Van Damme J, Opdenakker G. 2009. Reverse degradomics, monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products. Electrophoresis. 30:2366-77.

  21. Hu J.*, P.E. Van den Steen*, Q.-X. A. Sang, and G. Opdenakker. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Disc. 2007, 6:480-498.(影响因子28.7

  22. Hu, J., V. Dubois, P. Chaltin, P. Fiten, C. Dillen, P. E. Van den Steen and G. Opdenakker. 2006. Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb. Chem. High Throughput Screen. 9:599-611.

  23. Martens, E., A. Leyssen, I. Van Aelst, P. Fiten, H. Piccard, J. Hu, F. J. Descamps, P. E. Van den Steen, P. Proost, J. Van Damme, M. G. Liuzzi, P. Riccio, E. Polverini and G. Opdenakker. 2007. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim. Biophys. Acta. 1770:178-186.

  24. Opdenakker, G., C. Dillen, P. Fiten, E. Martens, I. Van Aelst, P. E. Van den Steen, I. Nelissen, S. Starckx, F. J. Descamps, J. Hu, H. Piccard, J. Van Damme, M. R. Wormald, P. M. Rudd and R. A. Dwek. 2006. Remnant epitopes, autoimmunity and glycosylation.Biochim. Biophys. Acta. 1760:610-615.

  25. Hu, J., P. E. Van den Steen, C. Dillen and G. Opdenakker. 2005. Targeting neutrophil collagenases/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol. 70:535-544.

  26. Hu, J., P. Fiten, P. E. Van den Steen, P. Chaltin and G. Opdenakker. 2005. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Anal. Chem. 77:2116-2124.

  27. Hu, J., P. E. Van den Steen, M. Houde, T. T. Ilenchuk and G. Opdenakker. 2004. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity Comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem. Pharmacol. 67:1001-1009.

  28. Van Damme, E. J., B. Hause, J. Hu, A. Barre, P. Rouge, P. Proost, W. J. Peumans. 2002. Two distinct jacalin-related lectins with a different specificity and subcellular location are major vegetative storage proteins in the bark of the black mulberry tree. Plant Physiol. 130:757-769.

  29. Van Damme, E. J., J. Hu, A. Barre, B. Hause, G. Baggerman, P. Rouge, W. J. Peumans. 2001. Purification, characterization, immunolocalization and structural analysis of the abundant cytoplasmic beta-amylase from Calystegiasepium (hedge bindweed) rhizomes. Eur. J. Biochem. 268:6263-6273.